Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-3 of 3
Keywords: Recombinant human erythropoietin
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Subject Area:
Nephrology
Journal:
Nephron Clinical Practice
Nephron Clinical Practice (2010) 117 (1): c1–c7.
Published Online: 03 August 2010
... have been developed as in the case of recombinant human erythropoietin (rHuEPO). In 2008, the experience gained with this drug has prompted the development of a new guideline, currently in draft. In this review we critically discuss aspects related to EMEA guidelines, particularly focusing on rHuEPO...
Journal Articles
Subject Area:
Nephrology
Kentaro Kohagura, Yusuke Ohya, Shinyu Miyagi, Akio Ishida, Shizuko Yakabi, Kunitoshi Iseki, Nobuhisa Yamane, Shuichi Takishita
Journal:
Nephron Clinical Practice
Nephron Clinical Practice (2008) 108 (1): c41–c46.
Published Online: 17 December 2007
... hemodialysis (MHD) patients who require higher doses of recombinant human erythropoietin (rHuEPO) have higher cardiovascular mortality. However, it has not been examined whether there is correlation between the numbers of CD34+ cells, including EPCs and erythroid progenitor cells, and the dose of rHuEPO in MHD...
Journal Articles
Subject Area:
Nephrology
Journal:
Nephron Clinical Practice
Nephron Clinical Practice (2005) 101 (2): c79–c86.
Published Online: 22 June 2005
...Wei X. Lu; Charlotte Jones-Burton; Min Zhan; Daniel J. Salzberg; Jack Moore Jr.; Jeffrey C. Fink Background: Recombinant human erythropoietin (rHuEPO) is recommended pre-dialysis to correct the anemia of chronic kidney disease. This study evaluated the impact of pre-dialysis rHuEPO on mortality...
